Figure 1.
Treatment and management of metastatic colon cancer to the liver will require a multidisciplinary approach that includes identification of high-risk cohorts, understanding how to modulate the immune microenvironment, and identification of novel effective blood-based biomarkers to design targeted and real-time treatment for high-risk patients. Ultimately, successful management of these patients will acknowledge a balance of risk recurrence with their quality of life. Chemo, chemotherapy.